Cart
×
CureDuchenne Congratulates Dyne Therapeutics on Its Initial Public Offering
Nonprofit Provided Early-Stage Funding to Accelerate Treatments for Duchenne Muscular Dystrophy Newport Beach, CA (September 25, 2020) – CureDuchenne, a leading global nonprofit dedicated to finding and funding a cure […]
Santhera Announces Publication of Long-Term Clinical Data with Vamorolone in Patients with Duchenne Muscular Dystrophy
Pratteln, Switzerland, September 22, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that partner ReveraGen Biopharma Inc. and their academic collaborators have published new open-label, long-term clinical data on the safety, tolerability […]
CureDuchenne Ventures’ Portfolio Company Dyne Therapeutics Opens Their Initial Public Offering
CureDuchenne celebrates Dyne Therapeutics’ public offering on the Nasdaq, under the ticker “DYN”. Today’s initial public offering (IPO) will elevate Dyne’s financial position and accelerate Dyne’s lead programs, which includes […]
Santhera Announces Publication on Molecular Distinctions of Vamorolone Compared to Corticosteroids
Pratteln, Switzerland, September 14, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that Emory University scientists and partner ReveraGen Biopharma Inc. have published new data on the molecular mode of action of […]
Santhera Announces Full Enrollment of ReveraGen’s Pivotal VISION-DMD Study with Vamorolone in Duchenne Muscular Dystrophy
Pratteln, Switzerland, September 11, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that partner ReveraGen Biopharma Inc. has completed enrollment into the pivotal VISION-DMD study with vamorolone in patients with Duchenne muscular […]
Santhera Exercises Option to Obtain Worldwide Rights to Vamorolone in Duchenne Muscular Dystrophy and All Other Indications
• License gives Santhera worldwide rights to vamorolone, now also including the major marketsJapan and South Korea, and paves the way for partnering in additional indications• Agreements with Idorsia and […]
Sarepta Therapeutics Announces FDA Acceptance of Casimersen (SRP-4045) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45
— FDA grants Priority Review Status and sets regulatory action date for February 25, 2021 —— FDA has indicated it does not currently plan to hold an advisory committee meeting […]
Dyne Therapeutics Series B financing
CureDuchenne congratulates the incredible Dyne Therapeutics team, who recently announced closing $115M in equity financing to develop transformational therapies for patients with serious muscle diseases. We share this news in […]